Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

NCT05162118 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Advanced Pancreatic Cancer

Interventions

DRUG: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab

Sponsor

Zhejiang University